Researchers suggest bisphosphonate could potentially reduce the risk of colorectal cancer, but more randomized trials should be carried out to confirm their results, according to an Internal Medicine News report.
Researchers studied 1,866 postmenopausal women and found that using bisphosphonate for more than one year helped reduce the risk of colorectal cancer by 59 percent. The bisphosphonate used by a majority of women was alendronate, sold under the brand name Fosamax and made available under a generic brand. The positive effect of taking bisphosphonate after the one-year mark was not as significant, according to the report.
Read the news report about bisphosphonate and CRC.
Read other coverage about colorectal cancer:
- 10 Recent Findings on GI Quality Issues
- Pricetag of Treating CRC: $14.1B
- USPSTF Advises Against CRC Screening for Individuals Older Than 85
Researchers studied 1,866 postmenopausal women and found that using bisphosphonate for more than one year helped reduce the risk of colorectal cancer by 59 percent. The bisphosphonate used by a majority of women was alendronate, sold under the brand name Fosamax and made available under a generic brand. The positive effect of taking bisphosphonate after the one-year mark was not as significant, according to the report.
Read the news report about bisphosphonate and CRC.
Read other coverage about colorectal cancer:
- 10 Recent Findings on GI Quality Issues
- Pricetag of Treating CRC: $14.1B
- USPSTF Advises Against CRC Screening for Individuals Older Than 85